9
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Prognosis After Nephrectomy for Renal Cell Carcinoma

, , &
Pages 229-236 | Received 14 Jun 1993, Accepted 28 Oct 1993, Published online: 15 Feb 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Michael Borre, Benni Nerstrøm & Jens Overgaard. (1997) Erythrocyte Sedimentation Rate—A Predictor of Malignant Potential in Early Prostate Cancer. Acta Oncologica 36:7, pages 689-694.
Read now
Tómas Gudbjartsson, Gudmundur V. Einarsson & Jónas Magnússon. (1996) A Population-Based Analysis of Survival and Incidental Diagnosing of Renal Cell Carcinoma Patients in Iceland, 1971-1990. Scandinavian Journal of Urology and Nephrology 30:6, pages 451-455.
Read now

Articles from other publishers (11)

D. Furniss, P. Harnden, N. Ali, P. Royston, T. Eisen, R.T. Oliver & B.W. Hancock. (2008) Prognostic factors for renal cell carcinoma. Cancer Treatment Reviews 34:5, pages 407-426.
Crossref
John S. Lam, Tobias Klatte, Hyung L. Kim, Jean-Jacques Patard, Alberto Breda, Amnon Zisman, Allan J. Pantuck & Robert A. Figlin. (2008) Prognostic factors and selection for clinical studies of patients with kidney cancer. Critical Reviews in Oncology/Hematology 65:3, pages 235-262.
Crossref
M. R. Nowrousian. 2008. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology 207 248 .
Shomik Sengupta, Christine M. Lohse, John C. Cheville, Bradley C. Leibovich, R. Houston Thompson, W. Scott Webster, Igor Frank, Horst Zincke, Michael L. Blute & Eugene D. Kwon. (2006) The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 106:2, pages 304-312.
Crossref
C Walter, M Kruessell, A Gindele, H G Brochhagen, A Gossmann & P Landwehr. (2003) Imaging of renal lesions: evaluation of fast MRI and helical CT. The British Journal of Radiology 76:910, pages 696-703.
Crossref
M. Grabowski, T. Huzarski, J. Lubinski & A. Sikorski. (2002) Survival in patients with rare subtypes of renal cell carcinoma. BJU International 89:6, pages 599-600.
Crossref
M. R. Nowrousian. 2002. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology 63 100 .
William K Oh, Judith Manola, Andrew A Renshaw, David Brodkin, Kevin R Loughlin, Jerome P Richie, Charles L Shapiro & Philip W Kantoff. (2000) Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. Urology 55:1, pages 31-35.
Crossref
M Tomisawa, T Tokunaga, Y Oshika, T Tsuchida, Y Fukushima, H Sato, H Kijima, H Yamazaki, Y Ueyama, N Tamaoki & M Nakamura. (1999) Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. European Journal of Cancer 35:1, pages 133-137.
Crossref
Hiroaki Masuda, Yutaka Kurita, Ken Fukuta, Soichi Mugiya, Kazuo Suzuki & Kimio Fujita. (1998) Significant Prognostic Factors for 5-Year Survival after Curative Resection of Renal Cell Carcinoma. International Journal of Urology 5:5, pages 418-422.
Crossref
D. Schiavone, A. Isgrò, F. Migliorini, R. Puce, L. Lusuardi, A. Mofferdin, L. Luciani & G. Mobilio. (2019) Prognostic value of clinical parameters for renal cell carcinoma. Urologia Journal 64:2, pages 156-164.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.